Search alternatives:
point decrease » point increase (Expand Search)
non decrease » nn decrease (Expand Search), note decreased (Expand Search), fold decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
point decrease » point increase (Expand Search)
non decrease » nn decrease (Expand Search), note decreased (Expand Search), fold decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
561
-
562
-
563
-
564
Powdery Mildew Decreases the Radial Growth of Oak Trees with Cumulative and Delayed Effects over Years
Published 2016“…Oak infection was monitored at individual tree level, at two sites in southwestern France, over a five-year period (2001–2005). Mean infection severity was almost 75% (infected leaf area) at the end of the 2001 growing season, at both sites, but only about 40% in 2002, and 8%, 5% and 2% in 2003, 2004 and 2005, respectively. …”
-
565
Delta Kmax<sup>1</sup> with non-accelerated and accelerated CXL<sup>2</sup> protocols.
Published 2022Subjects: -
566
-
567
-
568
Results for K<sub>s</sub>/D = 3.62 × 10<sup>−4</sup>, (a) Power, (b) Frequency, and (c) Amplitude.
Published 2025Subjects: -
569
Results for K<sub>s</sub>/D = 1.51 × 10<sup>−4</sup> (a) Power, (b) Frequency, and (c) Amplitude.
Published 2025Subjects: -
570
Delphinidin alters VEGF-A splicing to increase VEGF-A<sub>165</sub>b and decrease total VEGF-A expression.
Published 2019“…<b>C)</b> Under both NG and HG condition, delphinidin significantly decreased the protein expression of total VEGF-A<sub>165</sub> (*p<0.05; n = 3 biological repeats; One-way ANOVA with Bonferroni post-hoc test for comparison between pairs). …”
-
571
-
572
-
573
-
574
-
575
Vectorized siRNA TMPRSS2-ERG IV-SQ impaired tumour growth and restored differentiation <i>in vivo</i>.
Published 2015“…<p><b>a.</b> SCID mice (n = 5/group) bearing VCaP tumour xenografts were injected intravenously either with NaCl 0.9%, non-vectorized siRNA TMPRSS2-ERG IV, NPs siRNA control-SQ or NPs siRNA TMPRSS2-ERG IV-SQ twice per week during 6 weeks (1.8 mg/kg/mouse cumulative dose). …”
-
576
Table_1_v2_A long waiting time from diagnosis to treatment decreases the survival of non-small cell lung cancer patients with stage IA1: A retrospective study.docx
Published 2022“…After adjusting for other confounders, the waiting time was identified as an independent prognostic factor.</p>Conclusions<p>A long waiting time before treatment may decrease the survival of stage IA1 NSCLC patients. …”
-
577
-
578
-
579
-
580